Faiez Zannad

Faiez Zannad, MD, PhD, FESC is Professor of Therapeutics at the University of Lorraine in Nancy, France. Cardiologist and heart failure specialist, PhD in clinical pharmacology (Oxford, UK). Head of the Division of Heart Failure and Hypertension and Director of the Inserm Clinical Investigation Center at “Institut Lorrain du Coeur et des Vaisseaux”, Nancy.

Professor Zannad leads two EU FP7 granted programs: HOMAGE (omics biomarkers for mechanistic phenotyping and prediction of drug response) and FIBROTARGETS (fibrosis as a biotarget).

As the primary investigator or member of oversight committees in major clinical trials, he pioneered and/or made significant contributions to evidence-based heart failure therapy, mainly mineralocorticoid receptor antagonists (RALES, EPHESUS, EMPHASIS-HF), and beta-blockers (CIBIS) as well as in major comorbid diseases such as sleep disordered breathing (SERVE-HF), autonomic nervous dysfunction (NECTAR-HF, BEAT-HF), and diabetes (EXAMINE, EMPEROR), chronic kidney disease (FOSIDIAL, AURORA, ALCHEMIST), in diabetes (EXAMINE, EMPEROR), thrombosis in heart failure (COMMANDER-HF).

He served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on pharmacology and drug therapy, and board member of the ESC Heart Failure Association. He is the founder and is currently organizing the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international think tank gathering dedicated to the science of clinical trials, with meetings in Paris, Washington DC, Middle East and Asia.

As of 2016 Prof Zannad published more than 600 peer-reviewed papers. In 2014, he was awarded the European Society of Hypertension Paul Milliez Award and in 2017 the Lifetime Achievement Award from the ESC Heart Failure Association.